

Subserous Eosinophilic Colitis: A Case Report in a Private Hospital in Lima, Peru

Walter Zagaceta,^{1*} Miguel Valverde,² Jaker Mathios.³

OPEN ACCESS

Citation:

Zagaceta W, Valverde M, Mathios J. Subserous Eosinophilic Colitis: A Case Report in a Private Hospital in Lima, Peru. *Revista. colomb. Gastroenterol.* 2023;38(1):82-88. <https://doi.org/10.22516/25007440.888>

¹ Gastroenterologist. Medical Assistant of Gastroenterology, Clínica San Gabriel del Complejo Hospitalario San Pablo. Lima, Peru

² Gastroenterologist. Medical Assistant of Gastroenterology, Clínica San Gabriel del Complejo Hospitalario San Pablo. Lima, Peru

³ Gastroenterologist. Attending Physician of Gastroenterology. Clínica San Gabriel del Complejo Hospitalario San Pablo. Lima, Peru

*Correspondence: Walter Zagaceta.
zagaz_artemio@hotmail.com

Received: 15/02/2022

Accepted: 24/04/2022



Abstract

Eosinophilic colitis is a rare gastrointestinal disease that belongs to the group of so-called primary eosinophilic diseases of the digestive tract. There are three types: mucosa, transmural (muscular), and subserous. We present the case of a 23-year-old male patient with a clinical picture of abdominal pain, nausea, chronic diarrhea, and ascites. Parasitic and other secondary etiologies were ruled out. Upper digestive endoscopy was not helpful. Colonoscopy revealed characteristics of inflammation in the distal ileum and ascending colon, the histological findings of which were consistent with eosinophilic colitis. The study of ascitic fluid was suggestive of eosinophilic ascites. The patient received induction treatment with prednisone 40 mg daily orally; remission was achieved after two weeks, and maintenance therapy based on prednisone was continued with the progressive withdrawal of the dose. Control of the disease was successful.

Keywords

Colitis, colonic eosinophilia, eosinophilic ascites, eosinophilic gastroenteritis.

INTRODUCTION

Eosinophilic colitis is a rare gastrointestinal pathology.⁽¹⁾ The classic concept of primary eosinophilic diseases of the digestive tract (EGID) is that they share a common factor: the infiltration of eosinophils into the mucosa without having a known cause of peripheral eosinophilia. Although the latter is not usually present in many cases (as in eosinophilic esophagitis or eosinophilic colitis), the symptoms are essential to suspect these pathologies.⁽²⁾

Since the first publication in Germany in 1937 by Kaijser on EGID,⁽³⁾ isolated cases of these diseases have been presented in the literature, but currently, there are no clinical

guidelines in this regard, particularly for eosinophilic colitis. The latter is a disease poorly studied and requires well-defined criteria for its diagnosis and treatment.

PRESENTATION OF THE CASE

The following is a case of eosinophilic colitis with coexisting ascites, diagnosed and treated in a private hospital in Lima, Peru. We received a 23-year-old male patient who had been ill for six months and reported a clinical profile characterized by oppressive heart-type abdominal pain in the epigastrium, which subsequently migrated to the mesogastrium, associated with nausea, general malaise, and loss

of appetite. After three months, liquid, mucus-free, bloodless, non-enteric stools began to appear approximately three to four times a day, only during daylight.

In our hospital, the first tests requested (on October 6, 2021) were the following: hemoglobin (13.7 g/dL), hematocrit (39%), leukocytes (8980 cell/ μ L), eosinophils (38%), lymphocytes (15%), segmented neutrophils (40%), and platelets (208,000 cell/ μ L). From the main finding of peripheral eosinophilia, we began to look for etiologies, and the following results were obtained: *Toxoplasma gondii* immunoglobulin G (IgG) and M (IgM) negative, enzyme-linked immunosorbent assay (ELISA) for *Fasciola hepatica* negative, *Toxocara* IgG and IgM negative, immunoglobulin E (IgE) 67.3 IU/mL (normal), and antinuclear antibodies negative. The peripheral lamin described a red series of normal quantity and morphology, while the white series showed marked eosinophilia and normal morphology. The thrombocytic series resulted in a normal amount and morphology. Other outcomes were the following: lactate dehydrogenase (208 IU/L, normal), microglobulin β 2 (1.33 mg/L, normal), HIV (negative), hepatitis A and B profile (negative), Epstein-Barr IgG and IgM (negative), cytomegalovirus (CMV) IgG and IgM (negative), antigenic test for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) (negative), vitamin B₁₂ (482.1 pg/mL, normal), total protein (5.66 g/dL), albumin (4.03 g/dL), C-reactive protein (CRP) (9.8 mg/dl), and glucose (105 mg/dL). The functional stool examination was diarrheal, without steatorrhea, starches, food remains, red blood cells, negative Thevenon test, and negative inflammatory reaction. Parasites in feces (six samples) were negative.

The treating clinicians decided to start the search for the gastrointestinal etiology of eosinophilia associated with gastrointestinal symptoms presented by the patient. First, he underwent an endoscopy in which moderate erythematous gastritis (histopathological examination: mild superficial chronic gastritis, without *Helicobacter pylori*, atrophy, or intestinal metaplasia) and nonspecific duodenitis (histopathological examination: mild chronic duodenitis with intraepithelial lymphocytes 8-10/100 epithelial cells, without typical findings of a specific disease) were found. Then, he underwent a colonoscopy that presented the following findings: in the distal ileum, from approximately 15 cm from the ileocecal valve to the distal, marked mucosa congestion was observed with “punched” erosions, punctate erythema, and loss of mucosal vascularization (**Figure 1**). On histopathological examination, moderate chronic ileitis was found with no specific findings. In the cecum, at the level of the ileocecal valve and proximal to the appendicular orifice, erythema of the mucosa and partial loss of mucosal vascularization were observed (**Figure 2**). There was a significant increase in eosinophils at the

level of the lamina propria and crypts, which reached approximately > 200 eosinophils in a high-power field in the histopathological examination (**Figures 3 and 4**). This eosinophilic infiltrate was also accompanied by plasma cells, scarce lymphocytes, and cryptic abscesses, which are findings related to eosinophilic colitis.



Figure 1. Distal ileum. Source: Gastroenterology Service of Clínica San Gabriel.



Figure 2. Cecum. Source: Gastroenterology Service of Clínica San Gabriel.




Figure 3. Biopsy of the cecum. Overview of the microscopic image. Numerous eosinophils surround the crypts. Source: Pathological Anatomy area of Clínica San Gabriel.

The patient underwent an abdominal ultrasound in which an abdominopelvic free fluid was observed, approximately 1150 mL, determined by the four quadrants: the

liver had its morphology preserved with no signs of cirrhosis, and the rest of the organs of the abdominal cavity were within normal parameters. Due to the not-so-abundant amount of ascitic fluid, it was decided to perform an abdominal paracentesis oriented under ultrasound guidance (by interventional radiology), in which turbid yellow fluid was obtained without any bad odor, from which approximately 120 mL were extracted for studies. The following were the rest of the results: ascitic fluid cytochemistry, cell count (3150 cell/UL), polymorphonuclear (90%), mononuclear (10%), Gram stain (negative), glucose (100 mg/dL), albumin (3.56 g/dL), serum-ascites albumin gradient (GASA) (1.18), culture (negative), and adenosine deaminase (ADA) (5.53 IU/L, normal).




Figure 4. Cecum biopsy. It shows diffuse infiltration of eosinophils into the mucosa. Source: Pathological Anatomy area of Clínica San Gabriel.

With these findings, the diagnosis of subserous eosinophilic colitis was determined, so starting treatment with oral prednisone at doses of 40 mg per day for two weeks as induction therapy was decided. Blood count was monitored, and an improvement in symptoms and eosinophil count (successful clinical remission) was observed. Therefore, maintenance therapy was continued through progressive withdrawal of prednisone at a rate of 5 mg per week and reached up to 10 mg per day. The results were favorable (**Table 1**).

In the abdominal control ultrasound (15/12: after 30 days of maintenance therapy with prednisone), the liver of preserved morphology was observed, and there was no free fluid in the cavity. The rest of the organs had preserved characters.

DISCUSSION

Eosinophilic colitis is a gastrointestinal pathology that is part of the EGID group, along with eosinophilic esophagitis and eosinophilic gastroenteritis, which are defined by an excess count of eosinophils in the thickness of the wall of the gastrointestinal tract, without having an established secondary etiology. It is such a rare disease that, for example, in the United States, an overall prevalence of 2.1 per 100,000 people is reported, and it is more frequent in adults (1.6/100,000), unlike most EGIDs, which have an epidemiological inclination to pediatric populations. However, it is important to highlight that eosinophilic colitis has a bimodal pattern of

Table 1. Results of the patient's laboratory tests

	06/10	20/10	27/10 Initiation of induction therapy with prednisone	11/11 After 14 days of induction therapy	15/12 After 30 days of maintenance therapy
Hb (g/dL)	13,7	14,5	13,1	13,8	14,2
Hto (%)	39,3	40,1	37,2	40,6	41,9
Leu (cel/ μ L)	8980	11600	9710	10800	5300
Eos (%)	38	41	43	2	4
Eos (cel/μL)	3430	4830	4590	160	220
Lymph (%)	15		22	18	26
Seg (%)	40		30	73	59
CRP (mg/L)			9,8	0,49	0,7

Eos: eosinophils; Hb: hemoglobin; Hto: hematocrit; Leu: leukocytes; Lymph: lymphocytes; CRP: C-reactive protein; Seg: segmented. Source: Authors' own research.

presentation: first, in neonates and infants and then in adults. Due to its preponderance in urban and suburban areas, it may be related to high socioeconomic status or people with better levels of education.^(4,5)

The clinical profile of EGIDs depends on the level of involvement of eosinophilia in the gastrointestinal tract wall. According to the Klein classification, there are three types: mucosa (57.5%), including nausea, vomiting, abdominal pain, digestive bleeding, diarrhea, and others; muscular (30%), including intestinal obstruction (presented even as recurrent sigmoid volvulus) and gastrointestinal motility disorders; and serous (12.5%), including ascites, meteorism, peritonitis.^(6,7) Under this same criterion, we can say that the symptoms of eosinophilic colitis depend on the level of eosinophilic involvement, but they can occur in the same patient. Thus, in pediatric populations, there are clinical forms characterized by acute self-limited bloody diarrhea and, in adults, abdominal pain or chronic diarrhea, associated or not with the other symptoms described depending on the level of gastrointestinal involvement.⁽⁸⁾ In another review, three types of disease that do not differ much from the previous ones are described: mucosal, transmural, and subserous (the latter, which is the reason for this publication, with ascites, the most benign and, in turn, the most infrequent of the three).⁽⁵⁾

The finding of ascites by ultrasound, with the results of the sample exposed above, gives the form of subserous presentation to this disease so rare in our setting. Similarly, there have been cases reported in the literature with the presentation of eosinophilic ascites associated with gastroenteritis or colitis, such as the one reported by Cuko et al.,⁽⁹⁾ presenting a 37-year-old female patient whose leukocyte count in ascitic fluid was 8800, 94% polymorphonuclear (PMN), and with eosinophilic infiltrate in the duodenal mucosa. Likewise, in the case reported by Elsadeck,⁽¹⁰⁾ a 41-year-old male patient was described with gastroenteritis and colitis associated with infiltration of eosinophils, plasma cells, and lymphocytes at the mucosal level, in addition to the characteristic findings of eosinophilic ascites. Finally, a case reported by Amado et al.⁽¹⁾ describes a 55-year-old woman presenting with subserous eosinophilic colitis potentially triggered by an herbaceous product (they do not describe it as an etiology of colitis).

To diagnose this disease, it is important to know its differential diseases, listed in **Table 2**, including some drugs such as gabapentin and pregabalin.⁽¹¹⁾ It is relevant to note that eosinophilic colitis can mask colon adenocarcinoma, such as in the case reported by Milne et al.,⁽¹²⁾ or also be associated with another pathology such as Crohn's disease (*overlap*), as in the case described by Katsanos et al.⁽¹³⁾ It is relevant to know that biopsies are important for the diagnosis of eosinophilic colitis. However, it is essential to

differentiate it from the so-called *colonic eosinophilia* since, in the first one, the inflammatory infiltrate consists almost exclusively of eosinophils, unlike the second, in which there is a mixed inflammatory infiltrate and, generally, there is a known cause, such as allergies, drugs, inflammatory bowel disease, or infections, among others.⁽¹⁴⁾ In fact, the study conducted by Arévalo et al.⁽¹⁵⁾ found that, of 68 patients diagnosed with lymphocytic colitis (a subtype of microscopic colitis), there was a coexistence of 76.5% of elevated eosinophils in the colonic mucosa. The same study found that 51.4% of patients were diagnosed with eosinophilic colitis but only with biopsy, as the exclusion of other possible etiologies of eosinophilia is not described.

Table 2. Eosinophilic colitis: differential diagnoses⁽²⁾

Parasitic colitis
Eosinophilic gastroenteritis
Hypereosinophilic syndrome
Inflammatory bowel disease
Drug-induced colitis: <ul style="list-style-type: none"> - Nonsteroidal anti-inflammatory drugs - Rifampicin - Clozapine - Tacrolimus - Gold salts
Allogeneic bone marrow transplant
Other: Toulouse-Hunt syndrome, vasculitis (e.g., Churg-Strauss syndrome)
Acute radiation colitis

Taken from: Alfadda AA et al. *Therap Adv Gastroenterol.* 2011;4(5):301-9.

Endoscopic findings in patients with eosinophilic colitis are nonspecific. In fact, they may have a normal appearance in up to 70% of cases, so there may be overlap with diarrhea predominant-irritable bowel syndrome (IBS-D), as described by the study by Carmona-Sánchez et al.,⁽¹⁶⁾ which found a prevalence of 4.7% of patients with eosinophilic colitis who had also been diagnosed as IBS-D. Other common manifestations include erythema, edema, decreased mucosal vascularization, erosions, and ulcers. Regarding the location of the lesions, they can be found more frequently in the right and left colon and as pancolitis in up to 11% of cases.⁽⁶⁾ In our case, there were findings both in the distal ileum ("in punch" erosions, erythema, loss of mucosal vascularization) and in the cecum (erythema and loss of mucosal vascularization). In the other colon segments, there may have been the eosinophil counts necessary to diagnose eosinophilic colitis. However, the required samples were not obtained.

As already described above, a biopsy is essential. Nevertheless, eosinophils represent a normal component of inflammatory cells in the colon. Only they can vary in number in different colon segments, as they can also be part of the inflammatory infiltrate in various colon diseases.⁽¹⁷⁾ Eosinophilic density is usually estimated semiquantitatively and requires counting the number of eosinophils by high-power fields (HPF) and the mean count. This density is not yet clearly established to determine the diagnosis of eosinophilic colitis. However, some options have been proposed, such as more than 60 (or even 100) eosinophils/HPF, usually observed in the cecum^(18,19) or more than 40 eosinophils/HPF in at least two different segments of the colon.⁽⁶⁾ The finding was more than 200 eosinophils/HPF in our case. The other findings that can be found in histology are mentioned in **Table 3**.

Table 3. Microscopic findings in eosinophilic colitis⁽⁶⁾

Histological characteristics	Prevalence in eosinophilic colitis
Inflammatory mucosal infiltrate	100
Intraepithelial eosinophils	77
Eosinophilic degranulation	51
Architectural distortion	42
Acute inflammation	26
Mucosal atrophy	23
Eosinophilic microabscesses	21

Taken from: Macaigne G. Clin Res Hepatol Gastroenterol. 2020;44(5):630-637

Treating this disease is sometimes difficult, and no international guidelines define it. However, it has been reported that an improvement in gastrointestinal symptoms is observed with corticosteroids, mainly prednisone. Thus, its use in doses of 1-2 mg/kg/day orally for eight weeks with its progressive withdrawal (induction and maintenance therapies) has achieved effectiveness between 80% and

100% of cases.^(6,20) Clinical remission has also been achieved by induction therapy with oral prednisone (20-40 mg per day) for two weeks and subsequent maintenance therapy with progressive dose withdrawal, up to 5 mg daily.⁽⁵⁾ This last scheme was the one indicated in the patient and caused him to have remission of symptoms, as well as the normalization of eosinophilia after two weeks of induction with prednisone at 40 mg daily and later with progressive withdrawal, achieving a normal eosinophil count again at four weeks and absence of ascites. Furthermore, this form of treatment was indicated in some cases, such as the one described by Yep Gamarra et al.,⁽²¹⁾ which had a presentation of gastroenteritis with ascites, in that of Sánchez et al.,⁽²²⁾ and as in the case presented by Páramo-Zunzunegui et al.,⁽²³⁾ all with successful clinical remission.

In addition, there are other treatment schemes, such as the role of a hypoallergenic diet (even determined as a first therapeutic measure), anti-inflammatory agents such as mesalazine, immunomodulators such as azathioprine and antitumor necrosis factor (anti-TNF; infliximab and adalimumab) in refractory or steroid-dependent cases, and montelukast, among others.^(8,24)

CONCLUSIONS

After having made a detailed description of our clinical case of subserous eosinophilic colitis, we can say that this is an uncommon disease and that management guidelines on this pathology are still pending. When a patient has eosinophilia associated with gastrointestinal symptoms, an exhaustive search should be carried out to rule out secondary etiologies and accurately diagnose eosinophilic colitis. Corticosteroids such as prednisone are important because they mitigate gastrointestinal symptoms and improve laboratory and imaging parameters.

Acknowledgments

We thank Dr. Percy Terán Chávez for performing the diagnostic abdominal paracentesis under interventional radiology and Dr. Renier Cruz Baca, a pathologist doctor, for reading the intestinal biopsies.

REFERENCES

- Amado C, Silva Leal M, Neto P, Ferreira G. Subserous type of eosinophilic colitis: A rare disease. *Eur J Case Rep Intern Med.* 2021;8(7):002671. https://doi.org/10.12890/2021_002671
- Alfadda AA, Storr MA, Shaffer EA. Eosinophilic colitis: epidemiology, clinical features, and current management. *Therap Adv Gastroenterol.* 2011;4(5):301-9. <https://doi.org/10.1177/1756283X10392443>
- Ingle SB, Hinge Ingle CR. Eosinophilic gastroenteritis: an unusual type of gastroenteritis. *World J Gastroenterol.* 2013;19(31):5061-6. <https://doi.org/10.3748/wjg.v19.i31.5061>

4. Walker MM, Potter M, Talley NJ. Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus. *Lancet Gastroenterol Hepatol*. 2018;3(4):271-280.
[https://doi.org/10.1016/S2468-1253\(18\)30005-0](https://doi.org/10.1016/S2468-1253(18)30005-0)
5. Giudici G, Ribaldone DG, Astegiano M, Saracco GM, Pellicano R. Eosinophilic colitis: clinical review and 2020 update. *Minerva Gastroenterol Dietol*. 2020;66(2):157-163.
<https://doi.org/10.23736/S1121-421X.20.02656-2>
6. Macaigne G. Eosinophilic colitis in adults. *Clin Res Hepatol Gastroenterol*. 2020;44(5):630-637.
<https://doi.org/10.1016/j.clinre.2020.02.019>
7. Zucker K, Pradhan F, Gomez A, Nanda R. Eosinophilic Colitis in Recurrent Sigmoid Volvulus. *ACG Case Rep J*. 2021;8(8):e00650.
<https://doi.org/10.14309/crj.0000000000000650>
8. Impellizzeri G, Marasco G, Eusebi LH, Salfi N, Bazzoli F, Zagari RM. Eosinophilic colitis: A clinical review. *Dig Liver Dis*. 2019;51(6):769-773.
<https://doi.org/10.1016/j.dld.2019.04.011>
9. Cuko L, Bilaj F, Bega B, Barbullushi A, Resuli B. Eosinophilic ascites, as a rare presentation of eosinophilic gastroenteritis. *Hippokratia*. 2014;18(3):275-7
10. Elsadek H. Eosinophilic gastroenteritis presenting with ascites; case report and review of literature. *ZUMJ*. 2014;20(4):550-4.
<https://doi.org/10.21608/zumj.2014.4420>
11. Fragkos KC, Barragry J, Fernando CS, Novelli M, Begent J, Zárate-Lopez N. Severe eosinophilic colitis caused by neuropathic agents in a patient with chronic fatigue syndrome and functional abdominal pain: case report and review of the literature. *Z Gastroenterol*. 2018;56(6):573-577.
<https://doi.org/10.1055/a-0596-7981>
12. Milne DM, Rattan J, Muddeen A, Rambhajan AA. A Pink Herring in the Colon: A Case Report of Eosinophilic Colitis Masking Invasive Adenocarcinoma of the Colon. *Case Rep Surg*. 2020;2020:5641701.
<https://doi.org/10.1155/2020/5641701>
13. Katsanos KH, Zinovieva E, Lambri E, Tsianos EV. Eosinophilic-Crohn overlap colitis and review of the literature. *J Crohns Colitis*. 2011;5(3):256-61.
<https://doi.org/10.1016/j.crohns.2011.02.009>
14. Walker MM, Potter MD, Talley NJ. Eosinophilic colitis and colonic eosinophilia. *Curr Opin Gastroenterol*. 2019;35(1):42-50.
<https://doi.org/10.1097/MOG.0000000000000492>
15. Arévalo F, Aragón V, Montes P, Pérez Narrea T, Monge E. Colitis eosinofílica y colitis linfocítica: ¿diferentes manifestaciones histológicas de un mismo proceso en pacientes con diarrea crónica? *Rev Gastroenterol Peru*. 2013;33(1):39-42.
16. Carmona-Sánchez R, Carrera-Álvarez MA, Peña-Zepeda C. Prevalence of primary eosinophilic colitis in patients with chronic diarrhea and diarrhea-predominant irritable bowel syndrome. *Rev Gastroenterol Mex (Engl Ed)*. 2021:S0375-0906(21)00005-7.
<https://doi.org/10.1016/j.rgm.2020.11.002>
17. Patil DT, Odze RD. Biopsy diagnosis of colitis: an algorithmic approach. *Virchows Arch*. 2018;472(1):67-80.
<https://doi.org/10.1007/s00428-017-2274-0>
18. Bates AW. Diagnosing eosinophilic colitis: histopathological pattern or nosological entity? *Scientifica (Cairo)*. 2012;2012:682576.
<https://doi.org/10.6064/2012/682576>
19. Hua S, Cook D, Walker MM, Talley NJ. Pharmacological treatment of eosinophilic gastrointestinal disorders. *Expert Rev Clin Pharmacol*. 2016;9(9):1195-209.
<https://doi.org/10.1080/17512433.2016.1190268>
20. Díaz Del Arco C, Taxonera C, Olivares D, Fernández Aceñero MJ. Eosinophilic colitis: Case series and literature review. *Pathol Res Pract*. 2018;214(1):100-104.
<https://doi.org/10.1016/j.prp.2017.09.029>
21. Yep Gamarra V, Matos Nova A, Aldave Herrera A. Gastroenteritis Eosinofílica con Ascitis: Presentación de un Caso Clínico. *Rev Gastroenterol Perú*. 2011;31(2):173-7.
<https://doi.org/10.47892/rgp.2011.312.339>
22. Sánchez R, Zavala G, Lee B, Molina N. Colitis eosinofílica: reporte de un caso clínico. *Acta Gastroenterol Latinoam*. 2018;48(3):159-162.
23. Páramo-Zunzunegui J, Ortega-Fernandez I, Benito-Barbero S, Rubio-López L. Eosinophilic colitis: an infrequent disease with difficult diagnose. *BMJ Case Rep*. 2020;13(9):e235804.
<https://doi.org/10.1136/bcr-2020-235804>
24. El-Alali EA, Abukhiran IM, Alhmoud TZ. Successful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review. *BMC Gastroenterol*. 2021;21(1):279.
<https://doi.org/10.1186/s12876-021-01854-x>